Complement regulator factor H as a serum biomarker of multiple sclerosis disease state

Brain

Volumn 133, Issue 6, 2010, Pages 1602-1611

  Ingram, Gillian ^a   Hakobyan, Svetlana ^a   Hirst, Claire L ^a   Harris, Claire L ^a   Pickersgill, Trevor P ^b   Cossburn, Mark D ^a   Loveless, Sam ^a   Robertson, Neil P ^a   Morgan, Bryan Paul ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Alternative pathway; Biomarker; Complement; Factor H; Multiple sclerosis

Indexed keywords

COMPLEMENT FACTOR H;

ADULT; ARTICLE; CEREBROSPINAL FLUID LEVEL; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN VARIANT; UPREGULATION;

ADULT; BIOLOGICAL MARKERS; COMPLEMENT FACTOR H; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYMORPHISM, GENETIC; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 77952991177     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq085     Document Type: Article

References (57)

1. Barnum SR, Szalai AJ. Complement as a biomarker in Multiple sclerosis. J Neuropathol Exp Neurol 2005; 64: 741.
2. Berger T, Reindl M. Multiple sclerosis: disease biomarkers as indicated by pathophysiology. J Neurol Sci 2007; 259: 21-26
3. Brodeur JP, Ruddy S, Schwartz LB, Moxley G. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1531-1537
4. Carreno MP, Labarre D, Maillet F, Jozefowicz M, Kazatchkine MD. Regulation of the human alternative complement pathway: formation of a ternary complex between factor H, surface-bound C3b and chemical groups on nonactivating surfaces. Eur J Immunol 1989; 19: 2145-2150
5. Compston DA, Morgan BP, Oleesky D, Fifield R, Campbell AK. Cerebrospinal fluid C9 in demyelinating disease. Neurology 1986; 36: 1503-1506
6. Compston DA, Morgan BP, Campbell AK, Wilkins P, Cole G, Thomas ND, et al. Immunocytochemical localization of the terminal complement complex in Multiple sclerosis. Neuropathol Appl Neurobiol 1989; 15: 307-316
7. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 421-424
8. Eeg-Olofsson O, Link H, Wigertz A. Concentrations of CSF proteins as a measure of blood brain barrier function and synthesis of IgG within the CNS in 'normal' subjects from the age of 6 months to 30 years. Acta Paediatr Scand 1981; 70: 167-170
9. Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J, et al. Humoral immune response to EBV in Multiple sclerosis is associated with disease activity on MRI. Neurology 2009; 73: 32-38
10. Finehout EJ, Franck Z, Lee KH. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers 2005; 21: 93-101.
11. Gocke AR, Cravens PD, Ben LH, Hussain RZ, Northrop SC, Racke MK, et al. T-bet regulates the fate of Th1 and Th17 lymphocytes in auto-immunity. J Immunol 2007; 178: 1341-1348
12. Goverdhan SV, Lotery AJ, Cree AJ, Ye S. Complement factor H Y402H gene polymorphism in coronary artery disease and atherosclerosis. Atherosclerosis 2006; 188: 213-214
13. Hakobyan S, Harris CL, Tortajada A, Goicochea de Jorge E, Garcia-Layana A, Fernandez-Robredo P, et al. Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49: 1983-1990
14. Hamilton G, Proitsi P, Williams J, O'Donovan M, Owen M, Powell J, et al. Complement factor H Y402H polymorphism is not associated with late-onset alzheimer's disease. Neuromolecular Med 2007; 9: 331-334
15. Harris VK, Sadiq SA. Disease biomarkers in Multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther 2009; 13: 225-244
16. Hecker LA, Edwards AO, Ryu E, Tosakulwong N, Baratz KH, Brown WL, et al. Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet 2010; 19: 209-215
17. Hirst C, Ingram G, Pickersgill T, Swingler R, Compston D, Robertson N. Increasing prevalence and incidence of Multiple sclerosis in South East Wales. J Neurol Neurosurg Psychiatry. 2008 (In press).
18. Honda S, Itoh F, Yoshimoto M, Ohno S, Hinoda Y, Imai K. Association between complement regulatory protein factor H and AM34 antigen, detected in senile plaques. J Gerontol A Biol Sci Med Sci 2000; 55: M265-9.
19. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006; 129: 3042-3050
20. Ingram G, Hakobyan S, Robertson NP, Morgan BP. Complement in Multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol 2009; 155: 128-139
21. Jans H, Heltberg A, Zeeberg I, Kristensen JH, Fog T, Raun NE. Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive Multiple sclerosis. Acta Neurol Scand 1984; 69: 34-38
22. Jongen PJ, Doesburg WH, Ibrahim-Stappers JL, Lemmens WA, Hommes OR, Lamers KJ. Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand 2000; 101: 116-121
23. Kazatchkine MD, Fearon DT, Austen KF. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol 1979; 122: 75-81.
24. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007; 13: 1173-1175
25. Kurtzke JF. Rating neurologic impairment in Multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452
26. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from Multiple sclerosis. Lancet 2004; 364: 2106-2112 (Pubitemid 39626806)
27. Link H. Complement factors in Multiple sclerosis. Acta Neurol Scand 1972; 48: 521-528
28. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. II. Relation of the concentration of the proteins in serum and cerebrospinal fluid. Scand J Clin Lab Invest 1977; 37: 391-396
29. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of Multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717
30. Lutterotti A, Berger T, Reindl M. Biological markers for Multiple sclerosis. Curr Med Chem 2007; 14: 1956-1965
31. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of Multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996; 6: 259-274
32. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for Multiple sclerosis: guidelines from the International Panel on the diagnosis of Multiple sclerosis. Ann Neurol 2001; 50: 121-127
33. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007; 8: 913-919
34. Mollnes TE, Vandvik B, Lea T, Vartdal F. Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex. J Neurol Sci 1987; 78: 17-28.
35. Morgan BP, Campbell AK, Compston DA. Terminal component of complement (C9) in cerebrospinal fluid of patients with Multiple sclerosis. Lancet 1984; 324: 251-254
36. Oksjoki R, Jarva H, Kovanen PT, Laine P, Meri S, Pentikainen MO. Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol 2003; 23: 630-636
37. Pickering MC, Cook HT. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008; 151: 210-230
38. Rithidech KN, Honikel L, Milazzo M, Madigan D, Troxell R, Krupp LB. Protein expression profiles in pediatric Multiple sclerosis: potential bio-markers. Mult Scler 2009; 15: 455-464
39. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Multiple sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151
40. Sanders ME, Koski CL, Robbins D, Shin ML, Frank MM, Joiner KA. Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and Multiple sclerosis. J Immunol 1986; 136: 4456-4459
41. Scholl HP, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, Borncke F, et al. Systemic complement activation in age-related macular degeneration. PLoS One 2008; 3: e2593.
42. Schumacker GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965; 122: 552-568
43. Sellebjerg F, Jaliashvili I, Christiansen M, Garred P. Intrathecal activation of the complement system and disability in Multiple sclerosis. J Neurol Sci 1998; 157: 168-174 (Pubitemid 28218560)
44. Sjoberg AP, Trouw LA, Clark SJ, Sjolander J, Heinegard D, Sim RB, et al. The factor H variant associated with age-related macular degeneration (H384) and the non-disease associated form bind differentially to C-reactive protein, fibromodulin, DNA and necrotic cells. J Biol Chem 2007; 282: 10894-10900
45. Skerka C, Lauer N, Weinberger AA, Keilhauer CN, Suhnel J, Smith R, et al. Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol 2007; 44: 3398-3406
46. Stoop MP, Dekker LJ, Titulaer MK, Lamers RJ, Burgers PC, Sillevis Smitt PA, et al. Quantitative matrix-assisted laser desorption ioniza-tion-fourier transform ion cyclotron resonance (MALDI-FT-ICR) pep-tide profiling and identification of multiple-sclerosis-related proteins. J Proteome Res 2009; 8: 1404-1414
47. Taylor RW, Jobling MS, Turnbull DM, Chinnery PF. Frequency of rare mitochondrial DNA mutations in patients with suspected Leber's hereditary optic neuropathy. J Med Genet 2003; 40: e85.
48. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73: 1914-1922
49. Thambisetty M, Hye A, Foy C, Daly E, Glover A, Cooper A, et al. Proteome-based identification of plasma proteins associated with hip-pocampal metabolism in early Alzheimer's disease. J Neurol 2008; 255: 1712-1720
50. Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006; 176: 1305-1310
51. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977; 37: 385-390
52. Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in Multiple sclerosis. J Neurol 2008; 255(Suppl 1): 3-11.
53. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489
54. Woyciechowska JL, Brzosko WJ. Immunofluorescence study of brain plaques from two patients with Multiple sclerosis. Neurology 1977; 27: 620-622
55. Zeman AZ, Keir G, Luxton R, Thompson EJ. Serum oligoclonal IgG is a common and persistent finding in Multiple sclerosis, and has a systemic source. QJM 1996; 89: 187-193
56. Zetterberg M, Landgren S, Andersson ME, Palmer MS, Gustafson DR, Skoog I, et al. Association of complement factor H Y402H gene polymorphism with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 720-726
57. Zipfel PF, Jokiranta TS, Hellwage J, Koistinen V, Meri S. The factor H protein family. Immunopharmacology 1999; 42: 53-60.